Endotracheal neurofibroma in neurofibromatosis type 1: an unusual manifestation

Willmann, Jürgen K.; Weishaupt, Dominik; Kestenholz, Peter; Smekal, Alexander; Marinček, Borut

doi:10.1007/s003300100892

Cited by 25 publications

(2 citation statements)

References 0 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Obstruction of the upper airway with neurofibromas and neurofibromatosis, together with metastases of endobronchial schwannoma and fibrosarcoma, have been reported. [7][8][9] Endobronchial hamartoma alone is essentially a rare condition. 6 We did not find any association between endobronchial hamartoma and neurofibromatosis in the current literature.…”

Section: Discussionmentioning

confidence: 99%

Endobronchial hamartoma in a case with neurofibromatosis

et al. 2008

View full text Add to dashboard Cite

A 60-year-old male patient with neurofibromatosis type 1 presented with a right pulmonary mass. Bronchoscopic evaluation revealed an endobronchial mass on the right upper lobe.He was operated on after a bronchial biopsy and a fine-needle aspiration biopsy revealed non-specific findings. Pathological evaluation of right upper lobectomy material was compatible with an endobronchial hamartoma and right upper lobar abscess.Hamartoma is a component of neurofibromatosis syndrome. However, endobronchial hamartoma, as found in our patient, is a rare condition and is the reason for presenting this case.

show abstract

Section: Discussionmentioning

confidence: 99%

Endobronchial hamartoma in a case with neurofibromatosis

et al. 2008

View full text Add to dashboard Cite

show abstract

“…In addition to the very central focus of MDCT on the assessment of patients with CAD, MDCT recently has been found useful for the assessment of valvular disease. Both in patients with aortic [117, 118] and mitral stenosis [119, 120], valve leaflets could be visualized and valve opening measured directly. Dual-source scanners are already in the clinical arena [29] and further advances with 256-slice scanners, covering the heart in a single rotation, are in development [121].…”

Section: Present Limitations and Future Prospectsmentioning

confidence: 99%

Current Status and Clinical Applications of Cardiac Multidetector Computed Tomography

Halon

Rubinshtein²,

Gaspar³

et al. 2007

Cardiology

View full text Add to dashboard Cite

Contrast-enhanced multidetector-row computed tomography (MDCT) is now capable of providing high-quality noninvasive views of cardiac anatomy and ‘instant’ noninvasive coronary angiography. With current generation 64-slice scanners, MDCT can be performed in most patients with minimal patient discomfort and high diagnostic accuracy. MDCT may obviate the need for invasive diagnostic angiography in patients with borderline symptoms or equivocal noninvasive testing. It is useful in assessing the symptomatic patient postrevascularization and in emergency room triage in selected patients with chest pain. Calcified vessels are still difficult to assess, as is the accurate evaluation of implanted coronary stents. The volume of contrast material required for proper opacification limits the use of MDCT in patients with renal dysfunction, but newer emerging technologies will greatly improve these disadvantages in the near future. MDCT is expected to become an integral part of our diagnostic armamentarium in the cardiac patient.

show abstract

Multidetector CT coronary angiography: Where we are, and where we are going…

Pelzel

Lesser

Knickelbine

et al. 2006

Cathet Cardio Intervent

View full text Add to dashboard Cite

BACKGROUND Findings from the Groupe d'Etude des Lymphomes Adultes LNH 98‐5 study showed that rituximab added to combined cyclophosphamide, doxorubicin, vincristine, and prednisone (CHOP) prolonged progression‐free survival and overall survival in adults age ≥ 60 years with diffuse large B‐cell non‐Hodgkin lymphoma (DLBCL). The current study was conducted to investigate the incremental cost utility of the addition of rituximab to CHOP (R‐CHOP) compared with CHOP alone. METHODS Clinical prognosis of the time to disease progression and death was estimated using published evidence from the LNH 98‐5 study (n = 399 patients) that was linked mathematically to published long‐term outcome data on patients with DLBCL. Drug‐acquisition costs were based on published data from formulary pricing sources, and the costs of cancer surveillance and end‐of‐life care were based on published literature sources. The authors assessed cost utility as the difference in costs between R‐CHOP and CHOP divided by the increase in expected overall survival adjusted for quality of life. RESULTS Over 5 years, it was projected that R‐CHOP would prolong overall survival by 1.04 years. The mean cumulative cost of CHOP was $3358, and the mean cost of R‐CHOP was $17,225, resulting in a cumulative net increase of $13,867. The posttreatment cancer surveillance cost for CHOP was $3950, compared with $5202 for R‐CHOP. It was estimated that R‐CHOP would have a cost‐utility ratio of $19,297 per year of life gained compared with CHOP when adjusted for quality of life. R‐CHOP remained cost effective over wide ranges of variables in sensitivity analyses. CONCLUSIONS Compared with CHOP alone, it was predicted that R‐CHOP would be cost effective in elderly patients with DLBCL. Cancer 2005. © 2005 American Cancer Society.

show abstract

Endotracheal neurofibroma in neurofibromatosis type 1: an unusual manifestation

Cited by 25 publications

References 0 publications

Endobronchial hamartoma in a case with neurofibromatosis

Endobronchial hamartoma in a case with neurofibromatosis

Current Status and Clinical Applications of Cardiac Multidetector Computed Tomography

Multidetector CT coronary angiography: Where we are, and where we are going…

Contact Info

Product

Resources

About